Skip to Main Content

Biotech wants to know who’s betting against it. But investors and analysts suggest the industry get its house in order before demonizing its critics.

BIO, the industry’s largest trade group, is asking federal regulators to force short sellers — investors wagering that a stock price will fall — to publicly disclose who they are and what they’re doing, just as certain long-term investors are required to do. It’s not a new idea, but BIO’s reasoning — that biotech companies are particularly vulnerable victims of scare-mongering vultures empowered by anonymity — rankled more than a few investors and analysts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Regardless of which side of the isle you are on, shorting stocks is betting and destabilizes stock prices regardless whether the drug is inert or Effective especially in the early phases. I am not sure how you can enforce this , but the SEC should look further,

Comments are closed.